NET LOSS PER SHARE

6 Months Ended

Jun. 30, 2023

The following is a reconciliation of basic and diluted net loss per share:


	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2023		2022		2023		2022


Net loss	$	(2,886)	$	(333)	$	(9,692)	$	(9,433)

Weighted average number of shares - basic and diluted	22,704,723		19,792,286		22,587,022		19,693,216
Net loss per share - basic and diluted	$	(0.13)	$	(0.02)	$	(0.43)	$	(0.48)

Our basic and diluted net loss per share is computed using the two-class method. The two-class method is an earnings allocation that determines net income per share for each class of common stock and participating securities according to their participation rights in dividends and undistributed earnings or losses. Non-vested restricted stock that includes non-forfeitable rights to dividends are considered participating securities.

Because we have incurred a net loss for all periods presented, diluted net loss per common share is the same as basic net loss per common share. The following contingently issuable equity shares were excluded from the calculation of diluted net loss per share because their effect would have been anti-dilutive for all periods presented:


	Six Months Ended June 30,
	2023	2022


Restricted stock	580,162	433,093
Stock options	3,556	5,298

Total shares	583,718	438,391

The contingently issuable shares in the table above do not include shares of our common stock associated with our recent acquisitions of Pega Medical, ApiFix or MedTech. See Note 3 for additional information regarding future equity issuances under each of these acquisitions.